1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Primary Dysmenorrhea - Pipeline Review, H1 2014

Primary Dysmenorrhea - Pipeline Review, H1 2014

  • January 2014
  • -
  • Global Markets Direct
  • -
  • 39 pages

Primary Dysmenorrhea - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, 'Primary Dysmenorrhea - Pipeline Review, H1 2014', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Primary Dysmenorrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primary Dysmenorrhea. Primary Dysmenorrhea - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Primary Dysmenorrhea.
- A review of the Primary Dysmenorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Primary Dysmenorrhea pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Primary Dysmenorrhea.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Primary Dysmenorrhea pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Primary Dysmenorrhea - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Primary Dysmenorrhea Overview 6
Therapeutics Development 7
Pipeline Products for Primary Dysmenorrhea - Overview 7
Pipeline Products for Primary Dysmenorrhea - Comparative Analysis 8
Primary Dysmenorrhea - Therapeutics under Development by Companies 9
Primary Dysmenorrhea - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Primary Dysmenorrhea - Products under Development by Companies 12
Primary Dysmenorrhea - Companies Involved in Therapeutics Development 13
Merck and Co., Inc. 13
PDC Biotech GmbH 14
Jiangsu Kanion Pharmaceutical Co., Ltd. 15
Primary Dysmenorrhea - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Assessment by Therapeutic Class 25
Drug Profiles 27
KYG-0395 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
etonogestrel Vaginal Ring - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
PDC-31 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Peptidometics - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
PDC-41 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Primary Dysmenorrhea - Recent Pipeline Updates 32
Primary Dysmenorrhea - Dormant Projects 33
Primary Dysmenorrhea - Product Development Milestones 34
Featured News and Press Releases 34
Dec 10, 2012: PDC Biotech Completes Phase I Study Of PDC31 For Treatment Of Preterm Labor 34
Nov 01, 2012: Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related To Vioxx 34
Nov 15, 2010: PDC Biotech announces start of Phase l trial - novel peptide for treatment of preterm labour and primary dysmenorrhea 35
Jan 05, 2010: China Aoxing Pharmaceutical Announces Successful Completion Of Phase II Clinical Study Of TJSL For The Treatment Of Primary Dysmenorrhea 35
Feb 26, 2008: Sciele Pharma, Inc. Reports Results for Fourth Quarter and Year Ended December 31, 2007 35
Oct 30, 2007: Sciele Pharma, Inc. reports revenues and earnings for the third quarter of 2007. 36
Jul 25, 2007: Sciele Pharma, Inc. Reports Revenues and Earnings for the Second Quarter 2007 36
Apr 26, 2007: Sciele Pharma, Inc. reports results for the first quarter of 2007. 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables

Number of Products under Development for Primary Dysmenorrhea, H1 2014 7
Number of Products under Development for Primary Dysmenorrhea - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 10
Comparative Analysis by Early Stage Development, H1 2014 11
Products under Development by Companies, H1 2014 12
Primary Dysmenorrhea - Pipeline by Merck and Co., Inc., H1 2014 13
Primary Dysmenorrhea - Pipeline by PDC Biotech GmbH, H1 2014 14
Primary Dysmenorrhea - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2014 15
Assessment by Monotherapy Products, H1 2014 16
Number of Products by Stage and Target, H1 2014 18
Number of Products by Stage and Mechanism of Action, H1 2014 20
Number of Products by Stage and Route of Administration, H1 2014 22
Number of Products by Stage and Molecule Type, H1 2014 24
Number of Products by Stage and Therapeutic Class, H1 2014 26
Primary Dysmenorrhea Therapeutics - Recent Pipeline Updates, H1 2014 32
Primary Dysmenorrhea - Dormant Projects, H1 2014 33

List of Figures

Number of Products under Development for Primary Dysmenorrhea, H1 2014 7
Number of Products under Development for Primary Dysmenorrhea - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 10
Assessment by Monotherapy Products, H1 2014 16
Number of Products by Top 10 Target, H1 2014 17
Number of Products by Stage and Top 10 Target, H1 2014 18
Number of Products by Top 10 Mechanism of Action, H1 2014 19
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 20
Number of Products by Top 10 Route of Administration, H1 2014 21
Number of Products by Stage and Top 10 Route of Administration, H1 2014 22
Number of Products by Top 10 Molecule Type, H1 2014 23
Number of Products by Stage and Top 10 Molecule Type, H1 2014 24
Number of Products by Top 10 Therapeutic Class, H1 2014 25
Number of Products by Stage and Top 10 Therapeutic Class, H1 2014 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Canada Vision Care Market Outlook to 2022

Canada Vision Care Market Outlook to 2022

  • $ 4995
  • Industry report
  • December 2016
  • by Global Data

Canada Vision Care Market Outlook to 2022 Summary GlobalData’s new report, "Canada Vision Care Market Outlook to 2022", provides key market data on the Canada Vision Care market. The report provides ...

OTC Pharmaceuticals Global Industry Almanac_2016

OTC Pharmaceuticals Global Industry Almanac_2016

  • $ 2995
  • Industry report
  • October 2016
  • by MarketLine

Summary Global OTC Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2011-15, and forecast to 2020). ...

Global Topical Antibiotic Pharmaceuticals Market Research Report 2016

Global Topical Antibiotic Pharmaceuticals Market Research Report 2016

  • $ 2850
  • Industry report
  • November 2016
  • by 9Dimen Research

2016 Global Topical Antibiotic Pharmaceuticals Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Topical Antibiotic Pharmaceuticals industry, ...

Consumer Health In Japan

November 2016 $ 2423

Consumer Health In South Korea

October 2016 $ 2423

Consumer Health In China

September 2016 $ 2423

Consumer Health In Iran

September 2016 $ 2423

Download Unlimited Documents from Trusted Public Sources

Edible Seaweed Industry in the US

  • November 2016
    12 pages
  • Edible Seaweed  

    Fig  

  • United States  

View report >

OTC Markets in the US

  • October 2016
    6 pages
  • OTC  

  • United States  

View report >

OTC Markets in the US

  • October 2016
    6 pages
  • OTC  

  • United States  

View report >

Otc Industry In Europe

2 months ago

Global Otc Industry

2 months ago

Otc Industry In Japan

2 months ago

Otc Industry In The Us

2 months ago

Related Market Segments :

Pharmaceutical
Therapy
Dietary Supplement
Vitamin

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.